Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure (Nasdaq:XCUR) received a Nasdaq Listing Qualifications notice on May 28, 2026 for non-compliance with Rule 5250(c)(1) due to a delayed Form 10-Q for Q1 2026.

Rhea-AI Summary

Exicure (Nasdaq:XCUR) received a Nasdaq Listing Qualifications notice on May 28, 2026 for non-compliance with Rule 5250(c)(1) due to a delayed Form 10-Q for Q1 2026. The delay stemmed from changes in financial reporting personnel and procedures. Exicure filed the Form 10-Q on May 29, 2026 and believes it has regained compliance.

Positive

• Delayed Q1 2026 Form 10-Q filed on May 29, 2026
• Company believes Nasdaq Listing Rule 5250(c)(1) compliance has been regained

Negative

• Nasdaq delinquency notice received May 28, 2026 for late Q1 2026 Form 10-Q
• Non-compliance linked to changes in financial reporting personnel and procedures

Argus Jun 2 session

-6.61% close to close Open Argus

Details

News Market Reaction – XCUR

On Jun 2, the first trading day after this news, XCUR closed 6.61% below the previous close.

Data tracked by StockTitan Argus for the Jun 2 session.

Market Context

On Jun 2, the first trading day after this news, the stock closed 6.6% below the previous close. A n...

Analysis

On Jun 2, the first trading day after this news, the stock closed 6.6% below the previous close. A negative reaction despite the filing update would contrast with management’s view that Nasdaq compliance under Rule 5250(c)(1) had been regained after the May 29 Form 10-Q submission. Given recent disclosures of limited cash of $2.6 million, total liabilities of $10.7 million, and going-concern doubts, the market might focus more on structural risks than on procedural resolution, consistent with broader concerns seen in recent SEC filings.

Key Figures

Listing rule: Nasdaq Listing Rule 5250(c)(1) Quarter covered: Three months ended March 31, 2026 Notice date: May 28, 2026 +1 more

Listing rule

Nasdaq Listing Rule 5250(c)(1)

Non-compliance due to delayed Form 10-Q filing

Quarter covered

Three months ended March 31, 2026

Reporting period for the delayed Form 10-Q

Notice date

May 28, 2026

Nasdaq delinquency notification letter date

Filing date

May 29, 2026

Date Exicure filed the delayed Form 10-Q

Historical Context

5 past events · Latest: Apr 22

5 events

1. Apr 22

   Co-development deal

   24h Move

   +0.1%

   Co-development agreement for burixafor in multiple indications with Adbiotech.

2. Mar 25

   Full-year earnings

   24h Move

   +0.0%

   Full-year 2025 results highlighting liquidity shortfall and going-concern risks.

3. Feb 05

   Phase 2 publication

   24h Move

   +4.4%

   Publication of Phase 2 burixafor data showing rapid stem cell mobilization.

4. Jan 21

   Clinical data presentation

   24h Move

   +2.3%

   Announcement of Phase 2 burixafor data presentation with high primary endpoint success.

5. Dec 08

   Topline Phase 2 data

   24h Move

   +36.8%

   Positive topline Phase 2 burixafor results with strong mobilization and tolerability.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5250(c)(1), form 10-q

2 terms

nasdaq listing rule 5250(c)(1) regulatory

"not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing"

Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.

form 10-q regulatory

"delayed filing of its Quarterly Report on Form 10-Q for the three months ended"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) --  Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.

The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.

The Company filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission on May 29, 2026 and believes that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).

About Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company’s lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. For more information, visit www.exicuretx.com.

Cautionary Note Regarding Forward Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements related to the Company’s review and analysis in connection with the Form 10-Q and the Company’s expectations with respect to its financial results for the three months ended March 31, 2026 and the definitive filing date of the Form 10-Q. Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 25, 2026, as updated by the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.

Media Contact:

Exicure, Inc.

pr@exicuretx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Exicure (XCUR) receive a Nasdaq delinquency notice in May 2026?

Exicure received a Nasdaq delinquency notice on May 28, 2026 because it did not timely file its Form 10-Q for the quarter ended March 31, 2026. According to Exicure, the delay was mainly due to changes in financial reporting personnel and related filing procedures.

Is Exicure (XCUR) back in compliance with Nasdaq Listing Rule 5250(c)(1)?

Exicure believes it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its delayed Form 10-Q on May 29, 2026. According to Exicure, this filing addressed the deficiency that triggered Nasdaq’s May 28, 2026 notification letter.

What caused Exicure’s delay in filing its Q1 2026 Form 10-Q?

Exicure reports the Q1 2026 Form 10-Q was delayed primarily because it required additional time following changes in its financial reporting personnel and related filing procedures. According to Exicure, this timing issue led directly to the temporary Nasdaq listing rule non-compliance.

What key dates should Exicure (XCUR) investors know about the Nasdaq notice?

Investors should note May 28, 2026 as the date Exicure received the Nasdaq delinquency notice and May 29, 2026 as the Form 10-Q filing date. According to Exicure, it believes compliance with Listing Rule 5250(c)(1) has since been regained.

Which SEC filing was involved in Exicure’s Nasdaq compliance issue for XCUR stock?

The compliance issue involved Exicure’s Quarterly Report on Form 10-Q for the three months ended March 31, 2026. According to Exicure, this report was filed with the SEC on May 29, 2026 after an initial delay tied to internal reporting changes.

How might Exicure’s late Form 10-Q filing affect XCUR shareholders?

The late Form 10-Q prompted a Nasdaq delinquency notice but was followed by Exicure’s filing on May 29, 2026. According to Exicure, it believes compliance has been regained, which may reduce listing-related concerns for XCUR shareholders.